{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=3", "query": { "intervention": "Combination Agent 2", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 3607, "total_pages": 361, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T05:40:09.085Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01692301", "title": "Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Olmesartan", "type": "DRUG" }, { "name": "LCZ696 matching placebo", "type": "DRUG" }, { "name": "Olmesartan matching placebo", "type": "DRUG" }, { "name": "amlodipine", "type": "DRUG" }, { "name": "hydrochlorothiazide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 454, "start_date": "2012-12", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 11, "location_summary": "Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Belzoni", "state": "Mississippi" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT01692301" }, { "nct_id": "NCT01925612", "title": "Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-cell", "Lymphoma, Large B-cell, Diffuse" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2013-08", "completion_date": "2017-05-01", "has_results": true, "last_update_posted_date": "2018-06-21", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01925612" }, { "nct_id": "NCT01254136", "title": "Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "INCB007839 300mg BID", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2010-10", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2012-01-25", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 14, "location_summary": "Fayetteville, Arkansas • Duarte, California • Denver, Colorado + 11 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Davie", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01254136" }, { "nct_id": "NCT00666536", "title": "The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "valsartan and amlodipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 728, "start_date": "2008-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-10-27", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 1, "location_summary": "Metairie, Louisiana", "locations": [ { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666536" }, { "nct_id": "NCT03999411", "title": "Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Smoking", "Smoking Cessation", "HIV" ], "interventions": [ { "name": "Nicoderm C-Q Transdermal Product", "type": "DRUG" }, { "name": "Adherence to Antiretroviral Therapy Counseling", "type": "BEHAVIORAL" }, { "name": "Behavioral Smoking Cessation Counseling", "type": "BEHAVIORAL" }, { "name": "\"Crave-to-Quit\" app", "type": "BEHAVIORAL" }, { "name": "vDOT \"emocha\" app", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2019-09-09", "completion_date": "2020-10-14", "has_results": true, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03999411" }, { "nct_id": "NCT04165330", "title": "Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Soft Tissue Sarcoma", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer" ], "interventions": [ { "name": "AL3818", "type": "DRUG" }, { "name": "Nivolumab Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Oncology Research Center, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2019-10-17", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165330" }, { "nct_id": "NCT03765229", "title": "An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 11, "start_date": "2019-03-22", "completion_date": "2023-07-31", "has_results": true, "last_update_posted_date": "2024-01-10", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03765229" }, { "nct_id": "NCT04049539", "title": "Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells", "Persistent Disease", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2021-01-29", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 2, "location_summary": "Sacramento, California • Columbus, Ohio", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04049539" }, { "nct_id": "NCT02947711", "title": "Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "E2027", "type": "DRUG" }, { "name": "Diltiazem ER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 16, "start_date": "2016-10", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02947711" }, { "nct_id": "NCT05470400", "title": "A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "FP conjugate vaccine (25 mcg)", "type": "BIOLOGICAL" }, { "name": "FP conjugate vaccine (200 mcg)", "type": "BIOLOGICAL" }, { "name": "Trimer 6931 (100 mcg)", "type": "BIOLOGICAL" }, { "name": "Trimer 6931 (200 mcg)", "type": "BIOLOGICAL" }, { "name": "Trimer 4571 (200 mcg)", "type": "BIOLOGICAL" }, { "name": "Trimer 4571 (100 mcg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 44, "start_date": "2022-08-15", "completion_date": "2024-01-24", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-11-13T05:40:09.085Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05470400" } ] }